Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26114376 | 1.00 | CYP1A2 (0.48) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| SCHEMBL8577271 | 1.00 | CYP1A2 (0.48) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| SCHEMBL11212501 | 0.92 | CYP1A2 (0.46) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| SCHEMBL8291336 | 0.84 | GRM2 (0.32) | CYP1A2ALOX15GRM2GRM3 | |
| SCHEMBL26114807 | 0.82 | GRM2 (0.35) | CYP1A2ALOX15GRM2GRM3 | |
| SCHEMBL16894869 | 0.81 | CYP1A2 (0.38) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| SCHEMBL27172650 | 0.81 | CYP1A2 (0.38) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| SCHEMBL15152229 | 0.81 | CYP1A2 (0.38) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| SCHEMBL18135074 | 0.78 | BACE1 (0.42) | KMT2A | |
| SCHEMBL7018907 | 0.78 | BACE1 (0.42) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4684660-A | Mercaptoacyldepeptides | E. R. SQUIBB & SONS, INC. (US) | 1987-08-04 | — | — | US | claimed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| US-5801274-A | N- mercaptoacyl(amino acid or peptide)! compounds and S-lipophilic aliphatic carbonyl derivatives thereof as antihypertensives | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-09-01 | — | — | US | disclosed |
| US-5591891-A | PEPTIDASE INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1997-01-07 | — | — | US | disclosed |
| WO-1994017036-A1 | S-LIPOPHILIC ALIPHATIC CARBONYL [N-MERCAPTOACYL-(AMINO ACID OR PEPTIDE)] COMPOUNDS AS ANTIHYPERTENSIVE AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1994-08-04 | — | — | WO | disclosed |
| US-4684660-A | Mercaptoacyldepeptides | E. R. SQUIBB & SONS, INC. (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0053902-B1 | PHOSPHINYLALKANOYL SUBSTITUTED PROLINES | E.R. Squibb & Sons, Inc. (US) | 1985-04-03 | — | — | EP | disclosed |
| US-4384123-A | Phosphinylalkanoyl substituted prolines | E. R. SQUIBB & SONS, INC. (US) | 1983-05-17 | — | — | US | disclosed |
| US-4337201-A | Phosphinylalkanoyl substituted prolines | E. R. SQUIBB & SONS, INC. (US) | 1982-06-29 | — | — | US | disclosed |
| EP-0053902-A1 | Phosphinylalkanoyl substituted prolines | E.R. Squibb & Sons, Inc. (US) | 1982-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | CYP1A2 1522/4885ALOX15 148/4885GRM2 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.